StockWatch
·
Pharmaceuticals
Board Meeting5 Nov 2026, 04:20 pm

Windlas Biotech: revenue +18.7% YoY, margin squeeze caps PAT growth at 1.4%

AI Summary

Windlas Biotech's standalone revenue grew 18.7% YoY to ₹263.9 Cr in Q2 FY27 (quarter ended 30-Sep-2026), extending its growth run from ₹222.4 Cr a year ago, and rose 6.4% sequentially from ₹248.1 Cr in Q1 FY27. Profit after tax grew just 1.4% YoY to ₹18.05 Cr (₹17.80 Cr a year ago) and 2.3% QoQ (₹17.65 Cr) — profit growth trailing revenue growth by a wide margin, which is the core story of the quarter. Neither period carries exceptional items, so the gap is a genuine margin effect rather than a base-effect distortion. No Q2 FY27-specific street estimates for Windlas turned up in a search, so the print cannot be graded against consensus this quarter (vsStreet: unknown). Operating margin (EBITDA/revenue) came in near 11.1%, down from 12.8% a year ago though up slightly from 10.75% in Q1 FY27; net margin was 6.8%, down from 7.9% YoY and roughly flat sequentially (7.0%) — margin compression is a YoY phenomenon, not a QoQ one. Basic EPS of ₹8.75 rose 3.2% YoY and 3.4% QoQ, outpacing PAT growth, because the share count fell roughly 2.2% after the company completed a ₹47 Cr tender-offer buyback of 470,000 shares this half, on top of a ₹130 Cr FY26 dividend payout; both calls on cash were funded partly by a ₹16.4 Cr rise in short-term borrowings (₹29.9 Cr to ₹46.2 Cr). Management had guided on the Q1 FY27 call that Plant 6 would commercialize by the end of H1 FY27 — i.e., by this quarter-end — adding capacity toward ₹1,100 Cr of revenue. This filing does not name Plant 6 directly, but the balance sheet is consistent with that timeline: capital work-in-progress fell to nil from ₹56.2 Cr as of March 2026, while property, plant & equipment rose ₹29 Cr and right-of-use assets rose ₹35 Cr — a capitalization pattern that lines up with a facility going live in the exact window management flagged. No management press release accompanied this filing, so there is no fresh management commentary to check the numbers against this quarter. Separately, the same board meeting approved a leadership transition — Ashok Kumar Windlass stepped down as Whole-time Director as part of long-term succession planning, continuing as Senior Management Personnel/Founder President, while Hitesh Windlass was appointed Chairman — and the company had disclosed a cybersecurity incident on 30-Oct-2026, five days before results, with no financial impact quantified anywhere in this statement.

Key Highlights

  • Revenue +18.7% YoY to ₹263.9 Cr (vs ₹222.4 Cr), +6.4% QoQ (vs ₹248.1 Cr in Q1 FY27) — standalone basis
  • PAT +1.4% YoY to ₹18.05 Cr (vs ₹17.80 Cr), +2.3% QoQ (vs ₹17.65 Cr) — profit growth well behind revenue growth
  • OPM ~11.1% vs 12.8% a year ago (down) and 10.75% last quarter (up slightly); NPM 6.8% vs 7.9% YoY, ~flat QoQ at 7.0%
  • EPS ₹8.75, +3.2% YoY / +3.4% QoQ — ahead of PAT growth due to ~2.2% lower share count after a ₹47 Cr buyback of 470,000 shares this half
  • Capital work-in-progress fell to nil from ₹56.2 Cr as PP&E rose ₹29 Cr and right-of-use assets rose ₹35 Cr in H1 FY27 — consistent with Plant 6's capitalization in management's guided H1 FY27 commercialization window
  • Board approved a leadership transition: Ashok Kumar Windlass steps down as Whole-time Director (succession planning), continuing as Senior Management Personnel/Founder President; Hitesh Windlass appointed Chairman, effective 5-Nov-2026
  • Company disclosed a cybersecurity incident on 30-Oct-2026, days before results; no financial impact quantified in this filing